355 related articles for article (PubMed ID: 17289677)
1. Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense.
Johnson CL; Owen DM; Gale M
J Biol Chem; 2007 Apr; 282(14):10792-803. PubMed ID: 17289677
[TBL] [Abstract][Full Text] [Related]
2. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors.
Liang Y; Ishida H; Lenz O; Lin TI; Nyanguile O; Simmen K; Pyles RB; Bourne N; Yi M; Li K; Lemon SM
Gastroenterology; 2008 Nov; 135(5):1710-1718.e2. PubMed ID: 18725224
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A.
Vazquez C; Tan CY; Horner SM
J Virol; 2019 Dec; 93(23):. PubMed ID: 31534039
[TBL] [Abstract][Full Text] [Related]
4. Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0.
Horner SM; Park HS; Gale M
J Virol; 2012 Mar; 86(6):3112-20. PubMed ID: 22238314
[TBL] [Abstract][Full Text] [Related]
5. Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations.
Kalkeri G; Lin C; Gopilan J; Sloan K; Rijnbrand R; Kwong AD
Antimicrob Agents Chemother; 2013 Sep; 57(9):4417-26. PubMed ID: 23836176
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression.
Kaukinen P; Sillanpää M; Kotenko S; Lin R; Hiscott J; Melén K; Julkunen I
Virol J; 2006 Sep; 3():66. PubMed ID: 16945160
[TBL] [Abstract][Full Text] [Related]
7. GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS.
Chen Z; Benureau Y; Rijnbrand R; Yi J; Wang T; Warter L; Lanford RE; Weinman SA; Lemon SM; Martin A; Li K
J Virol; 2007 Jan; 81(2):964-76. PubMed ID: 17093192
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity.
Nitta S; Sakamoto N; Nakagawa M; Kakinuma S; Mishima K; Kusano-Kitazume A; Kiyohashi K; Murakawa M; Nishimura-Sakurai Y; Azuma S; Tasaka-Fujita M; Asahina Y; Yoneyama M; Fujita T; Watanabe M
Hepatology; 2013 Jan; 57(1):46-58. PubMed ID: 22911572
[TBL] [Abstract][Full Text] [Related]
9. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling.
Foy E; Li K; Sumpter R; Loo YM; Johnson CL; Wang C; Fish PM; Yoneyama M; Fujita T; Lemon SM; Gale M
Proc Natl Acad Sci U S A; 2005 Feb; 102(8):2986-91. PubMed ID: 15710892
[TBL] [Abstract][Full Text] [Related]
10. Limited suppression of the interferon-beta production by hepatitis C virus serine protease in cultured human hepatocytes.
Dansako H; Ikeda M; Kato N
FEBS J; 2007 Aug; 274(16):4161-76. PubMed ID: 17651439
[TBL] [Abstract][Full Text] [Related]
11. Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway.
Paz S; Sun Q; Nakhaei P; Romieu-Mourez R; Goubau D; Julkunen I; Lin R; Hiscott J
Cell Mol Biol (Noisy-le-grand); 2006 May; 52(1):17-28. PubMed ID: 16914100
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage.
Welsch C; Haselow K; Gouttenoire J; Schneider M; Morikawa K; Martinez Y; Susser S; Sarrazin C; Zeuzem S; Antes I; Moradpour D; Lange CM
J Hepatol; 2015 Apr; 62(4):779-84. PubMed ID: 25463536
[TBL] [Abstract][Full Text] [Related]
13. Recruitment of an interferon molecular signaling complex to the mitochondrial membrane: disruption by hepatitis C virus NS3-4A protease.
Hiscott J; Lacoste J; Lin R
Biochem Pharmacol; 2006 Nov; 72(11):1477-84. PubMed ID: 16876765
[TBL] [Abstract][Full Text] [Related]
14. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.
Loo YM; Owen DM; Li K; Erickson AK; Johnson CL; Fish PM; Carney DS; Wang T; Ishida H; Yoneyama M; Fujita T; Saito T; Lee WM; Hagedorn CH; Lau DT; Weinman SA; Lemon SM; Gale M
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):6001-6. PubMed ID: 16585524
[TBL] [Abstract][Full Text] [Related]
15. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.
Morikawa K; Lange CM; Gouttenoire J; Meylan E; Brass V; Penin F; Moradpour D
J Viral Hepat; 2011 May; 18(5):305-15. PubMed ID: 21470343
[TBL] [Abstract][Full Text] [Related]
16. MDA5 plays a critical role in interferon response during hepatitis C virus infection.
Cao X; Ding Q; Lu J; Tao W; Huang B; Zhao Y; Niu J; Liu YJ; Zhong J
J Hepatol; 2015 Apr; 62(4):771-8. PubMed ID: 25463548
[TBL] [Abstract][Full Text] [Related]
17. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.
Meylan E; Curran J; Hofmann K; Moradpour D; Binder M; Bartenschlager R; Tschopp J
Nature; 2005 Oct; 437(7062):1167-72. PubMed ID: 16177806
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity.
Ding Q; Cao X; Lu J; Huang B; Liu YJ; Kato N; Shu HB; Zhong J
J Hepatol; 2013 Jul; 59(1):52-8. PubMed ID: 23542348
[TBL] [Abstract][Full Text] [Related]
19. Importin β1 targeting by hepatitis C virus NS3/4A protein restricts IRF3 and NF-κB signaling of IFNB1 antiviral response.
Gagné B; Tremblay N; Park AY; Baril M; Lamarre D
Traffic; 2017 Jun; 18(6):362-377. PubMed ID: 28295920
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus NS3/4A protease blocks IL-28 production.
Ding Q; Huang B; Lu J; Liu YJ; Zhong J
Eur J Immunol; 2012 Sep; 42(9):2374-82. PubMed ID: 22685015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
